Patrys Limited Overview
Patrys Limited is an ASX-listed micro-cap biotechnology company that, over 2025–2026, transformed itself from a preclinical oncology antibody developer into a clinical-stage drug reformulation company. Its lead asset, RLS-2202, is a proprietary intravenous formulation of quetiapine — an established oral atypical antipsychotic — being developed to treat delirium in intensive care, aged care and palliative settings, where no drug is approved and clinicians rely on off-label agents. Acquired via the January 2026 purchase of Reliis Pty Ltd, the program entered a Phase 1a healthy-volunteer study in Adelaide in September 2026 and is intended to pursue the US FDA 505(b)(2) pathway, which allows reliance on existing quetiapine safety data. Patrys's legacy deoxymab antibody platform has been assigned to Yale University in exchange for a 50% share of future commercialisation revenue. The company holds A$3.36M cash, no debt, and remains dependent on equity markets to fund operations.
What the company does
Patrys is a drug development company with no commercial products, no revenue and an outsourced operating model. Its activities consist of (i) directing contract research organisations (CROs), contract development and manufacturing organisations (CDMOs) and clinical sites to generate data on its drug candidates, (ii) building and defending intellectual property, and (iii) seeking to create value via clinical milestones that can lead to licensing, partnering or acquisition.
The company's own description in its most recent disclosures (Phase 1a dosing announcement, 23 Sep 2026) characterises Patrys as a clinical-stage company developing an injectable therapy for delirium, alongside a differentiated deoxymab platform targeting immune-mediated inflammatory diseases. The FY2024 Annual Report, by contrast, described the company as leveraging its proprietary deoxymab antibody platform to develop therapies for cancer and other diseases — illustrating the scale of the 2025–26 pivot.
Business model and revenue model
| Revenue model element | Status | Commentary |
|---|---|---|
| Product sales | — | No approved products |
| Services | — | — |
| Subscription | — | — |
| Licensing / royalties | None currently; potential future | The 13 Jul 2026 Yale agreement entitles Patrys to 50% of Yale's future deoxymab commercialisation revenue (cash, equity, licensing income, royalties, milestones). Historical licensing income was A$27.5k in FY2022 (Hefei Co-Source / PAT-SC1) and nil thereafter. |
| Government grants (R&D Tax Incentive) | Historically material; nil recognised FY2026 | A$3.30M (FY2022), A$2.78M (FY2023), A$1.29M (FY2024), A$0.81M (FY2025), nil (FY2026). For FY2026 management judged there was insufficient evidence to recognise an R&D incentive receivable (AASB 120 judgement). |
| Interest | Minor | A$9.0k in FY2026 |
Intended monetisation path (company presentation, Jul 2026): develop RLS-2202 through Phase 1a (healthy volunteers) and Phase 1b (ICU delirium patients), file an FDA pre-IND (targeted Q1 2027) and IND (targeted Q1 2028), and identify a "potential partnering / licensing point" around the Phase 1b/pivotal transition. The company cites a total development cost of roughly US$20–30M over 3–5 years for the reformulation, versus a commonly cited ~US$1.2B and 10–15 years for a new molecular entity (company presentation; these are management estimates, not audited figures).
Value chain position
Patrys sits at the asset-ownership / development-management layer of the pharmaceutical value chain. It does not discover new molecules (quetiapine is a known drug), does not manufacture (BioCina, Adelaide, performed engineering and GMP batches), and does not run clinical sites (CMAX, Adelaide) or trial management (Alithia Life Sciences). Its value-add is the proprietary formulation IP, the regulatory strategy (505(b)(2)), and capital allocation.
Customer types and end-markets (prospective)
| Prospective customer | End-market | Notes |
|---|---|---|
| Hospitals / ICUs | Critical care delirium | Company cites up to 80% of ICU patients experiencing delirium (Richardson et al. cited in presentation) |
| Aged-care facilities | Geriatric delirium / agitation | Stated target setting |
| Palliative care | Terminal agitation / delirium | Stated target setting |
| Pharma licensees | Partnering | Most likely near-term "customer" for the asset |
| Yale University / Nucleicon (Yale venture) | Deoxymab platform | Patrys is a passive 50% revenue participant |
Independent characterisation
Patrys is best described as a single-asset, early-clinical, specialty-pharma reformulation shell with a residual antibody royalty interest. The legacy company (antibody discovery, 2007–2025) consumed approximately A$88.9M of accumulated losses (balance at 30 June 2026) without producing a clinical-grade drug for its deoxymab program; the board and management were replaced in 2025–26 by a Perth-based group with capital-markets and micro-cap biotech backgrounds, which bought in Reliis via an all-scrip transaction. The investment case now rests almost entirely on RLS-2202 producing a clean pharmacokinetic/safety profile and on the company's ability to fund a Phase 1b ICU study and FDA interactions.
Strategy
Stated strategy themes (paraphrased from 2026 disclosures)
-
Reformulate a proven drug for a faster, lower-risk path — take quetiapine, with decades of human safety data, into an IV form for acute care; use 505(b)(2) to rely on existing data.
-
Capital-efficient execution — conduct manufacturing and CMC work alongside Phase 1a to move quickly into Phase 1b; company estimates US$20–30M total development cost.
-
De-risk across value drivers — management argues the asset carries lower market, IP, manufacturing, regulatory and adoption risk than a typical biotech program (management's own risk matrix; not independently validated).
-
Monetise the legacy platform without funding it — the Yale assignment preserves 50% economic exposure to deoxymabs while removing most future R&D cost.
-
Partnering / licensing — the company flags a potential partnering point around Phase 1b / pivotal transition.
Strategic initiatives in the last 24 months
| Initiative | Date | Description | Status |
|---|---|---|---|
| Corporate restructure & board renewal | Jun–Nov 2025 | Board replaced; CEO role made redundant; office moved to Perth; costs cut | Complete |
| Recapitalisation | Jun 2025 – Apr 2026 | A$308k placement; ~A$1.77M entitlement offer; 15:1 consolidation; A$3.15M placement + A$160k director placement | Complete |
| Reliis acquisition | Nov 2025 – Jan 2026 | All-scrip purchase of injectable quetiapine program | Complete |
| RLS-2202 Phase 1a | May – Q4 2026 | CMAX site, Alithia CRO, BioCina manufacturing, HREC approval, dosing | Ongoing |
| US regulatory engagement | From Mar-26 quarter | Preparing FDA pre-IND (target Q1 2027) | Ongoing |
| Deoxymab assignment to Yale | 13 Jul 2026 | 50% revenue share; Patrys contributes A$150,000 toward ongoing deoxymab costs (per StockWire X summary) | Binding agreement; completion mechanics not detailed |
| Cost rationalisation | FY2026 | Sigma-Aldrich CHOZN licence terminated 30 Jun 2026; staff reduced | Complete |
No ESG or sustainability commitments have been announced. No formal cost-programme targets were published.
Management guidance / targets (company presentation, Jul 2026, updated by Sep 2026 announcements)
| Milestone | Target |
|---|---|
| Ethics approval Phase 1a | Q3 2026 — achieved 28 Aug 2026 |
| Phase 1a initiation | Q3 2026 — achieved 23 Sep 2026 |
| Cohort 1 complete | Achieved 29 Sep 2026 |
| Safety Review Committee | October 2026 |
| GMP clinical batch release / Cohort 2 dosing | Q4 2026 |
| Phase 1a completion (final participant dosed) | Q4 CY2026 |
| FDA pre-IND submission | Q1 2027 |
| 6-month drug product stability for CMC | Q1 2027 |
| Phase 1b ethics approval | Q2 2027 |
| Phase 1b first patient dosed | Q3 2027 |
| Phase 1b completion | Q4 2027 |
| IND submission | Q1 2028 |
No revenue, earnings or cash-burn guidance has been issued.
Products & Services
Patrys has no marketed products. The pipeline is catalogued below, organised by program family.
Reformulation platform (Reliis)
RLS-2202 — intravenous (injectable) quetiapine (lead asset)
Description: A proprietary injectable formulation of quetiapine, an atypical antipsychotic long used orally for schizophrenia and bipolar disorder. Developed for rapid, predictable treatment of delirium in acute care.
Rationale (company presentation, Jul 2026): Oral quetiapine is the most commonly prescribed antipsychotic in delirium (company cites 47% share of antipsychotic use, ahead of haloperidol at 40%, per Alghadeer et al. 2024), but is slow-onset (1–2 hours) and hard to administer to agitated or sedated patients. The company argues IV dosing can reduce exposure to the active metabolite norquetiapine, which it links to many side effects.
Development stage: Phase 1a (first participants dosed Sep 2026). Cohort 1 (n=4) received both a reference oral quetiapine dose and RLS-2202; Cohort 2 GMP material manufactured; final dosing targeted Q4 CY2026.
Regulatory route: FDA 505(b)(2). Australian trial run under TGA Clinical Trial Notification (CTN) scheme.
IP: Australian provisional patent 2022901032; PCT/AU2023/050316; national phase entered Q4 2024 in the US, EU/UK and Australia, covering formulation composition, method of use in delirium, and delivery formulation; company states protection to ~2042, wholly owned with no trailing obligations. A further provisional application covering new IP was filed in 2026.
Manufacturing: BioCina (Adelaide) — engineering batch commenced March 2026 quarter; GMP manufacturing and filling for Cohort 2 completed by Sep 2026.
Target customer: ICU, aged-care and palliative-care prescribers; ultimately pharma licensee.
Pricing model: Not disclosed.
Note on naming: At acquisition (Nov 2025 – Jan 2026) the program was named RLS-2201; from the March 2026 quarter onward, disclosures refer to RLS-2202. The sources reviewed do not explicitly explain the change; it coincides with a new 2026 provisional patent filing and an IV-focused formulation. Investors should confirm the relationship in the audited FY2026 Annual Report.
Deoxymab antibody platform (legacy; being assigned to Yale)
| Candidate | Format | Key properties (company disclosures) | Status at Oct 2026 |
|---|---|---|---|
| PAT-DX1 | Dimer of humanised single-chain binding fragment of 3E10 | Cell- and nucleus-penetrating via ENT2 transporter; crosses blood-brain barrier; inhibits DNA damage repair; preclinical activity in glioma (with radiation), TNBC, metastasis models; inhibits NETosis | Phase 1 abandoned after GMP batch failed specification testing (2 Oct 2024); out-licensing sought; to be assigned to Yale |
| PAT-DX3 | Full-length humanised IgG of 3E10 | Same binding domain; better yield/stability; crossed BBB in healthy animals (Oct 2022; 3–4× uptake vs control); synthetic lethality in BRCA2-deficient models (Mar 2023); reduced kidney injury in ANCA vasculitis model (Apr 2024) | Preclinical; MCB and GLP-grade process established; to be assigned to Yale |
| PAT-DX1-NP | PAT-DX1 conjugated to nanoparticles carrying payloads | Targeted delivery to tumours | Preclinical (FY2023 pipeline chart) |
| Deoxymab conjugates (ADC / AOC concepts) | PAT-DX3 conjugated to nucleic acids / small molecules | Delivery into nucleus avoiding endosomal degradation | Exploratory partner-funded experiments (FY2023) |
All deoxymabs derive from 3E10, an autoantibody identified in a mouse model of systemic lupus erythematosus, licensed from Yale.
Deoxymab IP estate (FY2024 Annual Report): 12 active patent families, 18 granted patents and 32 pending applications, plus one international PCT application and one US provisional; protection potentially to at least 2044.
Legacy IgM antibodies (exited)
PAT-SM6 (natural human IgM; melanoma and multiple myeloma trials circa 2010–2015), PAT-LM1 and PAT-SC1 (gastric cancer; China rights with Hefei Co-Source terminated Sep 2022). No longer in development.
Financial Narrative
Sources: FY2023 Annual Report (FY2022 comparatives), FY2024 Annual Report, FY2026 Appendix 4E (FY2025 comparatives). All AUD thousands unless stated.
Income statement
Notes:
-
Share-based payments were embedded within R&D/admin expense lines in FY2022–FY2024 (disclosed in notes) and shown separately in FY2026; the "Total operating expenses" row sums the face-of-P&L lines only and does not double count.
-
EBITDA defined as pre-tax loss + D&A − interest income (no interest expense; no debt). FY2025 EBITDA includes the A$303.8k impairment (non-cash); excluding it, FY2025 EBITDA would be −A$2,681.5k. FY2022 D&A not disclosed in the documents reviewed.
-
FY2025 EPS (−2.20c) and FY2026 EPS are as reported post-consolidation; FY2022–FY2024 adjusted figures are reported values ×15.
-
Gross, operating, EBITDA and net margins and revenue CAGR are not meaningful (nil revenue).
Half-year split FY2026 (Appendix 4D / 4E): H1 FY2026 loss A$3,021,202 versus full-year loss A$3,414,590, implying an H2 loss of only ~A$393k. Given reported quarterly operating cash outflows of A$748k (Mar-26 quarter) and ~A$789k (Jun-26 quarter), the low implied H2 accounting loss likely reflects year-end reclassifications (e.g., acquisition accounting or capital-raising costs moving to equity) — a point to verify in the audited accounts.
Commentary. The P&L tells a story of a company that wound down a costly manufacturing-heavy antibody program. R&D spend fell 79% from A$8.09M (FY2022) to A$1.71M (FY2026). The key inflection was FY2024, when the PAT-DX1 GMP campaign concluded and spending halved; FY2025 then absorbed the October 2024 specification failure and a full write-off of the Nucleus IP. FY2026 R&D was nearly flat year-on-year in absolute terms but its composition changed completely — from deoxymab residual activity to RLS-2202 manufacturing (BioCina), regulatory and trial set-up. The most important adverse change in FY2026 is the loss of R&D Tax Incentive income (nil recognised vs A$807k in FY2025): the company did not lodge claims during the restructuring period and management judged that recognition criteria were not met at 30 June 2026. Any future recognition would be upside to reported income and cash.
Balance sheet
Commentary. The balance sheet bottomed at 30 June 2025 with equity of just A$733k and cash of A$742k — a near-distress position. FY2026 rebuilt it via ~A$5.0M of cash equity and ~A$7.85M of scrip issued for Reliis. The A$7.57M of goodwill and IPR&D now represents 68% of total assets; this intangible is valued using an income approach (Relief from Excess Earnings Method) with probability-of-success assumptions, and the company itself warns that changes in assumptions could cause a material change in value. Effective shareholder dilution since 30 June 2024 is ~4.9× on a consolidation-adjusted basis (137.1M → 666.5M shares). Trade payables jumped from A$136k to A$679k, reflecting trial and manufacturing activity.
Cash flow
Quarterly cash (Appendix 4C):
(Q4 outflow per Kalkine/Webull summaries of the June-quarter 4C describing ~A$789k of expenditure; treat as approximate.) The September-2026 quarter Appendix 4C (due by end-October 2026) was not located during this research.
Commentary. Free cash burn was reduced from ~A$8.7M (FY2022) to ~A$1.8M (FY2024–FY2025) through program wind-down, then rose to A$2.2M in FY2026 as RLS-2202 moved toward clinic and R&D refunds disappeared. At a run-rate of ~A$0.75–0.8M per quarter before trial cost escalation, the A$3.36M June 2026 cash balance implied roughly four quarters of runway — consistent with the directors' statement that further capital will be needed within twelve months. Phase 1b ICU work (targeted 2027) would require materially more capital.
Ratios
ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful (no revenue, no debt, no invested capital generating returns). The falling ROA denominator in FY2026 reflects the acquired intangible, not improved economics.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Segment revenue — Biopharma R&D (AUD K) | 0 | 0 | 0 | 0 | 0 |
Segment other income — Biopharma R&D (AUD K) | 3,333.6 | 2,851.9 | 1,394.2 | 828.5 | 9.0 |
Segment pre-tax loss — Biopharma R&D (AUD K) | -6,780.4 | -7,061.6 | -3,539.2 | -3,013.3 | -3,414.6 |
Contribution to group revenue (%) | 0 | 0 | 0 | 0 | 0 |
Group Entities
| Entity | Role | Program |
|---|---|---|
Patrys Limited | Listed parent; board, capital raising | Group |
Reliis Pty Ltd | Wholly owned since 28 Jan 2026 | RLS-2202 (injectable/IV quetiapine), carried as A$6.75M IPR&D intangible plus A$0.82M goodwill |
Nucleus Therapeutics Pty Ltd | Wholly owned since 2016 | Deoxymab IP (PAT-DX1, PAT-DX3), carrying value nil; to be assigned to Yale under 13 Jul 2026 agreement |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD K) | 0 | 0 | 0 | 0 | 0 |
R&D Tax Incentive income (AUD K) | 3,298.0 | 2,775.0 | 1,285.0 | 807.3 | 0 |
Interest income (AUD K) | 8.1 | 76.9 | 109.1 | 21.3 | 9.0 |
Licensing income (AUD K) | 27.5 | 0 | 0 | 0 | 0 |
Total other income (AUD K) | 3,333.6 | 2,851.9 | 1,394.2 | 828.5 | 9.0 |
R&D expense (AUD K) | 8,085.2 | 7,524.8 | 3,071.8 | 1,754.2 | 1,706.4 |
Administration & management expense (AUD K) | 2,028.7 | 2,388.7 | 1,861.5 | 1,783.9 | 1,567.2 |
Impairment of intangibles (AUD K) | 0 | 0 | 0 | 303.8 | 0 |
Share-based payments expense (AUD K) | 572.1 | 465.5 | 163.3 | 0 | 150.0 |
Total operating expenses (AUD K) | 10,113.9 | 9,913.5 | 4,933.3 | 3,841.8 | 3,423.6 |
Gross profit (AUD K) | 0 | 0 | 0 | 0 | 0 |
Operating result before other income (AUD K) | -10,113.9 | -9,913.5 | -4,933.3 | -3,841.8 | -3,423.6 |
Depreciation & amortisation (AUD K) | — | 47.0 | 47.0 | 49.3 | 0.3 |
EBITDA (AUD K) | — | -7,091.5 | -3,601.3 | -2,985.3 | -3,423.2 |
Pre-tax loss (AUD K) | -6,780.4 | -7,061.6 | -3,539.2 | -3,013.3 | -3,414.6 |
Income tax (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net loss (AUD K) | -6,780.4 | -7,061.6 | -3,539.2 | -3,013.3 | -3,414.6 |
Basic EPS as reported (AUD cents) | -0.3458 | -0.3436 | -0.1722 | -2.20 | -0.83 |
Basic EPS consolidation-adjusted (AUD cents) | -5.19 | -5.15 | -2.58 | -2.20 | -0.83 |
Diluted EPS (AUD cents, as reported) | -0.3458 | -0.3436 | -0.1722 | -2.20 | -0.83 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Balance Sheet and Share Count (millions)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash & cash equivalents (AUD K) | 7,817.8 | 3,045.5 | 2,240.7 | 742.4 | 3,360.1 |
Term deposits >3 months (AUD K) | 2,004.0 | 1,000.0 | 0 | 0 | 0 |
Trade & other receivables (AUD K) | 3,411.3 | 2,842.1 | 1,341.8 | 825.3 | 100.5 |
Total current assets (AUD K) | 13,527.6 | 7,129.1 | 3,808.5 | 1,739.1 | 3,523.2 |
Goodwill (AUD K) | 0 | 0 | 0 | 0 | 820.0 |
Other intangibles (AUD K) | 438.8 | 393.8 | 348.8 | 0 | 6,750.0 |
Total assets (AUD K) | 13,970.0 | 7,524.5 | 4,161.6 | 1,739.1 | 11,096.7 |
Total liabilities (AUD K) | 542.8 | 686.9 | 691.4 | 1,006.2 | 918.6 |
Short-term debt (AUD K) | 0 | 0 | 0 | 0 | 0 |
Long-term debt (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net debt incl. term deposits (AUD K) | -9,821.8 | -4,045.5 | -2,240.7 | -742.4 | -3,360.1 |
Total equity (AUD K) | 13,427.2 | 6,837.6 | 3,470.2 | 732.9 | 10,178.2 |
Issued capital (AUD K) | 85,723.7 | 85,730.1 | 85,734.4 | 86,010.4 | 94,214.6 |
Accumulated losses (AUD K) | -74,296.3 | -81,119.4 | -83,874.2 | -86,203.0 | -88,875.5 |
Working capital as reported ex-prepayments (AUD K) | 12,690.3 | 6,200.7 | 2,893.7 | 561.5 | 2,604.7 |
Shares on issue at year end (millions, as reported) | 2,055.3 | 2,055.6 | 2,055.8 | 2,364.1 | 666.5 |
Shares on issue at year end (millions, consolidation-adjusted) | 137.0 | 137.0 | 137.1 | 157.6 | 666.5 |
NTA per share (AUD cents, as reported) | 0.63 | 0.31 | 0.15 | 0.05 | 0.05 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD K) | -8,679.2 | -5,778.8 | -1,815.9 | -1,774.2 | -2,170.1 |
of which R&D Tax Incentive receipts (AUD K) | 1,188.6 | 3,347.3 | 2,731.6 | 1,285.0 | 807.2 |
Payments to suppliers & employees (AUD K) | -9,906.3 | -9,202.9 | -4,650.6 | -3,081.0 | -2,986.3 |
Capex (AUD K) | -2.3 | 0 | -3.2 | 0 | -3.9 |
Free cash flow (AUD K) | -8,681.5 | -5,778.8 | -1,819.2 | -1,774.2 | -2,174.0 |
Gross equity proceeds (AUD K) | 7,901.6 | 6.4 | 4.3 | 308.4 | 5,034.6 |
Net financing cash flow (AUD K) | 7,556.4 | 6.4 | 4.3 | 276.0 | 4,791.7 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (AUD K) | 870.9 | -4,772.4 | -804.9 | -1,498.2 | 2,617.7 |
Key Financials
| Metric | Q2 FY2026 (Dec-25) | Q3 FY2026 (Mar-26) | Q4 FY2026 (Jun-26) |
|---|---|---|---|
Net operating cash outflow (AUD K) | 674 | 748 | 789 |
Closing cash (AUD K) | 1,904 | 1,196 | 3,360 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | -53.2 | -69.7 | -68.7 | -143.4 | -62.6 |
ROA on year-end assets (%) | -48.5 | -93.8 | -85.0 | -173.3 | -30.8 |
Current ratio (x) | 24.9 | 10.4 | 5.5 | 1.7 | 3.8 |
Debt to equity (x) | 0 | 0 | 0 | 0 | 0 |
R&D as % of total operating expenses (%) | 79.9 | 75.9 | 62.3 | 45.7 | 49.8 |
R&D net of R&D Tax Incentive income (AUD K) | 4,787.2 | 4,749.8 | 1,786.8 | 946.9 | 1,706.4 |
Geographic Revenue
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Revenue — Australia (AUD K) | 0 | 0 | 0 |
Revenue — Americas (AUD K) | 0 | 0 | 0 |
Revenue — EMEA (AUD K) | 0 | 0 | 0 |
Revenue — Rest of APAC (AUD K) | 0 | 0 | 0 |
Share Price
| Metric | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Share price at FY end as reported (AUD) | 0.056 | 0.020 | 0.010 | 0.007 |
Share price at FY end consolidation-adjusted (AUD) | 0.84 | 0.30 | 0.15 | 0.105 |
Valuation Multiples
| Multiple | Patrys | Comment |
|---|---|---|
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales | n/m | No revenue |
P/B | ~2.5x | A$25.64M market cap / A$10.18M equity (30 Jun 2026) |
P/tangible book | ~9.8x | Tangible equity ~A$2.61M after excluding A$7.57M intangibles |
EV | A$22.3M | Company figure, 24 Jul 2026 |
Capital Instruments
| Instrument | Number | Terms | Source |
|---|---|---|---|
Underwriting fee options | 68,666,660 | A$0.024, exp. 30 Nov 2029 | FY2026 4E |
Broker fee options | 9,999,996 | A$0.024, exp. 30 Nov 2029 | FY2026 4E |
Sub-underwriting options (Christie, Uvarov) | 7,499,999 | A$0.024, exp. 30 Nov 2029 | FY2026 4E |
Leedman incentive options | 5,000,000 | A$0.040, exp. 10 Feb 2029 | FY2026 4E |
April 2026 placement attaching options | ~33M (1 for 4) | A$0.048 | ASX 20 Apr 2026 (subject to approval; obtained 8 Jun 2026) |
Reliis performance rights | 70,000,000 | Milestone-based | FY2026 4E |
Analyst Conclusions
Management guidance
Clinical milestone guidance only: Phase 1a completion Q4 CY2026, FDA pre-IND Q1 2027, Phase 1b first patient Q3 2027, IND Q1 2028. No financial guidance. Directors expect to require additional capital within twelve months of 31 Aug 2026.
Consensus
None (no broker coverage).
Bull case
-
Execution credibility: the new team took an acquired asset from completion (Jan 2026) to first-in-human dosing (Sep 2026) in under eight months, on the timetable promised in May 2026.
-
Asymmetric market structure: with no approved delirium drug and quetiapine already the most-used antipsychotic in delirium, a clean PK/safety bridge could make RLS-2202 a credible licensing target at a modest development cost (company estimate US$20–30M).
-
Free optionality: the 50% deoxymab revenue interest and residual R&D Tax Incentive claims provide upside not reflected in a ~A$22M EV.
Bear case
-
Financing overhang: A$3.36M cash, quarterly burn ~A$0.8M before Phase 1b costs, and a going-concern uncertainty point to further dilutive raises — likely before value-inflecting Phase 1b data.
-
Clinical/regulatory unknowns: IV antipsychotic safety, FDA acceptance of bridging, and the historic difficulty of proving efficacy in delirium could each delay or derail the program.
-
Track record and governance: accumulated losses of A$88.9M, the PAT-DX1 manufacturing failures, a board with limited independence, and an intangible-heavy balance sheet (68% of assets) warrant a significant risk discount.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst |
|---|---|
| Oct 2026 | Safety Review Committee decision on Cohort 1; Cohort 2 dosing commencement |
| Late Oct 2026 | Sep-26 quarter Appendix 4C (cash runway) |
| Oct–Nov 2026 | Audited FY2026 Annual Report (confirm going-concern wording, remuneration, top-20 holders); AGM |
| Q4 CY2026 | Final Phase 1a dosing; top-line PK/safety readout timing |
| Q1 2027 | FDA pre-IND submission and feedback; 6-month CMC stability data |
| H1 2027 | Capital raise (high probability) and R&D Tax Incentive claim/receipt |
| Q2–Q3 2027 | Phase 1b ethics approval and first ICU patient dosed |
| Ongoing | Yale/Nucleicon progress on deoxymabs; any partnering discussions |
Analyst verdict
Patrys Limited in October 2026 is a fundamentally different company from the one that listed in 2007. Nearly two decades and roughly A$89M of accumulated losses were spent on antibody platforms — first natural human IgMs, then Yale's cell-penetrating deoxymabs — without a clinical-grade product reaching patients; the October 2024 PAT-DX1 specification failure effectively ended that chapter and pushed the company to the brink, with equity of under A$1M by June 2025. The subsequent recapitalisation, board replacement and all-scrip acquisition of Reliis have produced a credible, focused story: an IV formulation of quetiapine for delirium, now in human testing, pursued via a regulatory route that leans on decades of existing data.
The operational evidence since January 2026 is encouraging — every guided milestone through Cohort 1 completion has been met on time — and the Yale transaction sensibly converts a cash drain into a free option. The scientific premise is reasonable: clinicians already favour quetiapine in delirium, and the main obstacle is the route of administration.
However, the investment case remains binary and capital-constrained. Phase 1a will only establish PK and tolerability; proof of clinical benefit must await Phase 1b in ICU patients (targeted 2027) and ultimately a global pivotal study the company cannot fund alone. With A$3.36M cash at June 2026, an explicit going-concern uncertainty, roughly 28% potential dilution from outstanding options and rights, and a balance sheet dominated by an income-approach IPR&D valuation, near-term equity raises appear unavoidable. Governance — a small, closely held board including vendor directors — adds further risk.
On balance, Patrys suits only speculative, high-risk capital: the risk/reward hinges on a clean Phase 1a readout and constructive FDA pre-IND feedback, which together would materially improve its ability to raise funds or attract a partner. Absent those, dilution is likely to erode per-share value.
All figures from company filings unless otherwise noted; FY2026 figures unaudited.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Compensation |
|---|---|---|---|---|
Dr Samantha South | Chief Executive Officer | Since 16 Feb 2026 | Founding Director of Argenica Therapeutics (ASX: AGN) and former VP Non-Clinical Development there (2023–24 per MarketScreener); former NED of Reliis Pty Ltd before its acquisition; Chair of Life Sciences WA board; CNS research background; prior preclinical/regulatory roles at CROs; ~15 years in medtech/biotech technology transfer; PhD, MBA, GAICD | Not publicly disclosed in sources reviewed (FY2026 remuneration report not located) |
Johnathon Busing and Kieran Witt | Joint Company Secretaries | Since 10 Nov 2025 | Not detailed in sources reviewed | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Appointed | Background | Independence (analyst view) |
|---|---|---|---|---|
Peter Christie | Non-Executive Chair | Director from 17 Jun 2025; Chair during 2025 | 25+ years ASX governance; Chair of Moho Resources (ASX: MOH); NED Mount Ridley Mines (ASX: MRD); former Chair 3D Medical; former director ResApp Health; Curtin University graduate (1983); former portfolio manager, Allstate Investment Management | Participated in 2025–26 raisings and sub-underwriting; likely independent under ASX definitions but a material option holder |
Dr Anton Uvarov | Non-Executive Director | Elected AGM 9 Oct 2025 | Former Citigroup healthcare equities analyst; co-founder/director of multiple ASX companies including BlinkLab, Elsight, Dimerix, Actinogen, Neuroscientific Biopharmaceuticals | Significant shareholder and sub-underwriter (6.67M sub-underwriting options); not independent in substance |
Brian Leedman | Non-Executive Director | 10 Nov 2025 | Co-founder of ResApp Health (acquired by Pfizer); chair/director roles at BlinkLab, Alcidion, OncoSil, Neuroscientific Biopharmaceuticals | Received 5M incentive options (A$0.04, exp. 10 Feb 2029); likely independent |
Leanne Kite | Non-Executive Director | 28 Jan 2026 | Co-founder of Reliis; 20+ years capital markets, finance and IR; IR for Liontown Resources; 13 years in senior finance roles at Woodside Energy (per StockWire X) | Reliis vendor; holds 36.6M shares — not independent |
Dino Cercarelli | Non-Executive Director | 28 Jan 2026 | Co-founder of Reliis; COO of Australian Clinical Trials Alliance; clinical trial operations leader | Reliis vendor; holds 21.4M shares — not independent |
Board of Directors (Annual)
| Name | Role | Total FY2023 (AUD) | Total FY2024 (AUD) | Notes |
|---|---|---|---|---|
Dr James Campbell | MD & CEO (13 Apr 2015 – 30 Jun 2025) | 735,443 | 487,074 | FY2023 included A$104,085 bonus and A$221,558 share-based payments; FY2024 salary A$372,649, super A$27,500, SBP A$43,397. Package A$416,555 from 1 Jul 2024. Role made redundant 1 Jul 2025; received 10.7M shares at A$0.015 (A$160,527) in Oct 2025 in lieu of accrued salary and non-statutory termination payments. |
Dr Charmaine Gittleson | Chair (16 Nov 2022 – 2025) | 83,768 | 106,943 | Fee A$95,430 p.a. |
Dr Pamela Klein | NED (Oct 2019 – 2025) | 90,524 | 91,425 | Paid USD 60,000 |
Suzy Jones | NED (Dec 2011 – Sep 2023) | 97,964 | 18,758 | — |
Michael Stork | NED / Deputy Chair (Feb 2007 – 2025) | 1,247 | 0 | No cash fees; held 98.8M shares (pre-consolidation) via Stork Holdings |
Total KMP | — | 1,039,621 | 704,200 | — |
Board & Management Changes
| Date | Change |
|---|---|
17 Jun 2025 | Peter Christie appointed director |
1 Jul 2025 | CEO role made redundant; Campbell becomes NED |
9 Oct 2025 | AGM elects Christie and Uvarov; re-elects Campbell |
10 Nov 2025 | Campbell resigns; Leedman appointed; Busing and Witt appointed joint company secretaries |
28 Jan 2026 | Kite and Cercarelli appointed on Reliis completion |
16 Feb 2026 | Dr Samantha South commences as CEO |
Directors' Shareholdings
| Director | Shares | Options / rights | Source |
|---|---|---|---|
Leanne Kite | 36,629,087 | — | MarketIndex (28 Jan 2026) |
Dino Cercarelli | 21,433,740 | — | MarketIndex (28 Jan 2026) |
Anton Uvarov | — | 6,666,666 sub-underwriting options at A$0.024, exp. 30 Nov 2029 | InvestSMART director-interest log; FY2026 4E |
Peter Christie | — | 833,333 sub-underwriting options at A$0.024 | Same |
Brian Leedman | 2,000,000 | 5,000,000 options at A$0.04 | MarketIndex (10 Feb 2026) |
Competitive Landscape
Key Competitors
| Competitor / product | Owner | Relevance | Positioning vs RLS-2202 |
|---|---|---|---|
IV/IM haloperidol (generic) | Multiple generic makers | Most-used typical antipsychotic in delirium (company cites 40% share) | Cheap, entrenched; QTc and extrapyramidal risk |
Dexmedetomidine IV (Precedex and generics) | Pfizer/Hospira and generics | ICU sedation used off-label for agitated delirium | Strong ICU incumbency; sedation-focused |
Sublingual dexmedetomidine (Igalmi) | BioXcel Therapeutics | Approved for agitation in schizophrenia/bipolar, not delirium | Shows regulatory precedent for reformulated acute-agitation products |
Oral quetiapine (generic) | Multiple | Most-prescribed antipsychotic in delirium (company cites 47%) | Same molecule; slow onset; RLS-2202 aims to supersede in acute settings |
Olanzapine (oral/IM/sublingual) | Lilly and generics | Off-label use (company cites 9%) | Alternative atypical |
Risperidone (generic) | Multiple | Off-label use (company cites 4%) | — |
Benzodiazepines / sedatives | Multiple | Used despite worsening some delirium | Generally not recommended |
IL-6 inhibitors, minocycline | Various | Listed by Patrys as being assessed in delirium | Early-stage alternative mechanisms |
Key Competitors by Peer
| Peer | Ticker | Relevance |
|---|---|---|
Argenica Therapeutics | ASX: AGN | CNS neuroprotection; CEO's former company |
Actinogen Medical | ASX: ACW | CNS; Uvarov board link |
Neuroscientific Biopharmaceuticals | ASX: NSB | CNS; Uvarov and Leedman links |
Dimerix | ASX: DXB | Inflammation/renal; Uvarov link |
Percheron Therapeutics | ASX: PER | Former Chair Gittleson's company |
Prescient Therapeutics | ASX: PTX | Former CEO Campbell's board seat |
BlinkLab | ASX: BB1 | Leedman/Uvarov-associated micro-cap |
BioXcel Therapeutics | NASDAQ: BTAI | Acute agitation reformulation precedent |
Competitor Detail
| Metric | Patrys (FY2026) |
|---|---|
Revenue | A$0 |
Revenue growth | n/m |
Net loss | A$3.41M |
R&D intensity (% of opex) | 49.8% |
Cash | A$3.36M |
Market cap | ~A$25.6M (Jul 2026) |



